Amy Krouse Rosenthal Foundation Research Grant for Early Detection of Ovarian Cancer supports researchers studying premalignant lesions and biomarkers to detect ovarian cancer and its recurrence.
Funder: Foundation for Women's Cancer
Due Dates: October 7, 2026 (LOI) | December 9, 2026 (Invited full proposals)
Funding Amounts: $72,500 for one year
Summary: Supports research on premalignant lesions and biomarkers for early detection of ovarian cancer and its recurrence.
Key Information: Research must take place at a U.S. institution; applicants need SGO membership, an SGO-member co-investigator, or an SGO sponsor.
The Amy Krouse Rosenthal Foundation Research Grant for Early Detection of Ovarian Cancer is offered through the Foundation for Women’s Cancer (FWC), within its 2026–2027 ovarian cancer research grants. It supports early detection and recurrence biomarker development, including research into the biology of premalignant lesions and early ovarian cancer.
Eligible research includes detecting premalignant lesions such as serous tubal intraepithelial carcinoma (STIC), using approaches such as serum or plasma analysis, uterine lavage, Pap smears, and fallopian tube sampling. The grant also supports biomarker development for detecting ovarian cancer, recurrence, or both. This includes identifying high-risk patients, such as BRCA or PALB2 mutation carriers, and developing early-detection methodologies for these populations.